Evidence map›Paper›PMID 37716912›Full record

ArticleClinical pharmacology and therapeutics2023

Clinician Response to Pharmacogenetic Clinical Decision Support Alerts.

Lauren K Lemke, Emily J Cicali, Roy Williams, Khoa A Nguyen, Larisa H Cavallari, Kristin Wiisanen

Open access · bronzeAbstract read
In one paragraph

Article in Clinical pharmacology and therapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Evaluation of CYP2C19 Clinical Decision Support Alerts to Guide P2YClinical pharmacology and therapeutics · 2025
    Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Lauren K LemkePharmacotherapy and Translational Research, University of Florida, Gainesville, Florida, USA.ORCID 0009-0006-6745-237X
Emily J CicaliPharmacotherapy and Translational Research, University of Florida, Gainesville, Florida, USA.ORCID 0000-0002-3595-9321
Roy WilliamsPharmacotherapy and Translational Research, University of Florida, Gainesville, Florida, USA.
Khoa A NguyenPharmacotherapy and Translational Research, University of Florida, Gainesville, Florida, USA.
Larisa H CavallariPharmacotherapy and Translational Research, University of Florida, Gainesville, Florida, USA.ORCID 0000-0002-7184-5292
Kristin WiisanenPharmacotherapy and Translational Research, University of Florida, Gainesville, Florida, USA.
University of Florida · US

Funding

Using social networks to map and evaluate team science across CTSA hubsUL1TR001427 · NCATS · UNIVERSITY OF FLORIDA · PI MITCHELL, DUANE A. · 2015 to 2024
$37.2M
Sparking Advancements in Genomic MedicineU01HG007269 · NHGRI · UNIVERSITY OF FLORIDA · PI CAVALLARI, LARISA HUMMA, JOHNSON, JULIE A. · 2013 to 2024
$17.0M
NCATS NIH HHS UL1 TR001427NHGRI NIH HHS U01 HG007269
6 · The paper itself

Abstract

The objective of this study was to characterize clinician response following standardization of pharmacogenetic (PGx) clinical decision support alerts at University of Florida (UF) Health. A retrospective analysis of all PGx alerts that fired at a tertiary academic medical center from August 2020 through May 2022 was performed. Alert acceptance rate was calculated and compared across six gene-drug pairs, patient care setting, and clinician specialty. The disposition of the triggering medication was compared with the alert response and evaluated for congruence. There were a total of 818 alerts included for analysis of alert response, 557 alerts included in acceptance rate calculations, and 392 alerts with sufficient information to assess clinical response. The overall acceptance rate was 63%. The alert response and clinical response were congruent for 47% of alerts. Alert response was influenced by the triggering gene-drug pair, clinician specialty, patient care setting, and specialty of the provider who initially ordered the PGx test. Clinical response was mostly incongruent with alert response. Alert acceptance is influenced by the triggering gene-drug pair, clinician specialty, and care setting. Alert response is not a reliable surrogate marker for clinical action. Any future research into the impact of clinical decision support (CDS) alerts should focus on clinical response rather than alert response. Given the reliance on CDS alerts to enhance uptake of PGx, it is worthwhile to further investigate their impact on prescribing and patient outcomes.

Indexed as

Decision Support Systems, ClinicalMedical Order Entry SystemsElectronic Health RecordsHumansPharmacogeneticsRetrospective Studies

Identifiers

PMID37716912
PMCPMC10726431
OpenAlexW4386797084

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.